SURROZEN INC (SRZN) Stock Fundamental Analysis

NASDAQ:SRZN • US86889P2083

26.36 USD
+0.61 (+2.37%)
Last: Feb 27, 2026, 10:17 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, SRZN scores 2 out of 10 in our fundamental rating. SRZN was compared to 521 industry peers in the Biotechnology industry. While SRZN seems to be doing ok healthwise, there are quite some concerns on its profitability. SRZN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year SRZN has reported negative net income.
  • In the past year SRZN has reported a negative cash flow from operations.
  • In the past 5 years SRZN always reported negative net income.
  • SRZN had a negative operating cash flow in each of the past 5 years.
SRZN Yearly Net Income VS EBIT VS OCF VS FCFSRZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -92.41%, SRZN is doing worse than 73.32% of the companies in the same industry.
Industry RankSector Rank
ROA -92.41%
ROE N/A
ROIC N/A
ROA(3y)-88.27%
ROA(5y)-71.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SRZN Yearly ROA, ROE, ROICSRZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SRZN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SRZN Yearly Profit, Operating, Gross MarginsSRZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • SRZN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SRZN has been increased compared to 1 year ago.
  • The number of shares outstanding for SRZN has been reduced compared to 5 years ago.
  • There is no outstanding debt for SRZN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SRZN Yearly Shares OutstandingSRZN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
SRZN Yearly Total Debt VS Total AssetsSRZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -4.28, we must say that SRZN is in the distress zone and has some risk of bankruptcy.
  • SRZN has a Altman-Z score (-4.28) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.28
ROIC/WACCN/A
WACC8.69%
SRZN Yearly LT Debt VS Equity VS FCFSRZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 13.15 indicates that SRZN has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 13.15, SRZN belongs to the best of the industry, outperforming 88.87% of the companies in the same industry.
  • SRZN has a Quick Ratio of 13.15. This indicates that SRZN is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of SRZN (13.15) is better than 88.87% of its industry peers.
Industry RankSector Rank
Current Ratio 13.15
Quick Ratio 13.15
SRZN Yearly Current Assets VS Current LiabilitesSRZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • SRZN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -110.16%.
  • Looking at the last year, SRZN shows a very negative growth in Revenue. The Revenue has decreased by -63.96% in the last year.
EPS 1Y (TTM)-110.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1800%
Revenue 1Y (TTM)-63.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-90.17%

3.2 Future

  • SRZN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.05% yearly.
  • SRZN is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y21.3%
EPS Next 2Y31.09%
EPS Next 3Y20.41%
EPS Next 5Y10.05%
Revenue Next Year-31.51%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

SRZN Yearly Revenue VS EstimatesSRZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2024 2025 2030 2031 2032 2033 20M 40M 60M 80M 100M
SRZN Yearly EPS VS EstimatesSRZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SRZN. In the last year negative earnings were reported.
  • Also next year SRZN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRZN Price Earnings VS Forward Price EarningsSRZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRZN Per share dataSRZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SRZN's earnings are expected to grow with 20.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.09%
EPS Next 3Y20.41%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SRZN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SURROZEN INC

NASDAQ:SRZN (2/27/2026, 10:17:22 AM)

26.36

+0.61 (+2.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)03-30
Inst Owners84.33%
Inst Owner Change40.96%
Ins Owners0.57%
Ins Owner Change2.06%
Market Cap225.91M
Revenue(TTM)3.60M
Net Income(TTM)-86.91M
Analysts85
Price Target42.84 (62.52%)
Short Float %2.94%
Short Ratio1.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-148.45%
Min EPS beat(2)-622.12%
Max EPS beat(2)325.23%
EPS beat(4)1
Avg EPS beat(4)-292.69%
Min EPS beat(4)-622.12%
Max EPS beat(4)325.23%
EPS beat(8)4
Avg EPS beat(8)-135.54%
EPS beat(12)6
Avg EPS beat(12)-83.79%
EPS beat(16)9
Avg EPS beat(16)-59.81%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.51%
PT rev (3m)13.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.57%
EPS NY rev (1m)0%
EPS NY rev (3m)-243.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)14.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 62.68
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-22.34
EYN/A
EPS(NY)-4.31
Fwd EYN/A
FCF(TTM)-2.47
FCFYN/A
OCF(TTM)-2.46
OCFYN/A
SpS0.42
BVpS-2.74
TBVpS-2.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -92.41%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.27%
ROA(5y)-71.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.44%
Cap/Sales 2.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.15
Quick Ratio 13.15
Altman-Z -4.28
F-Score3
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)19.96%
Cap/Depr(5y)33.21%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-110.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1800%
EPS Next Y21.3%
EPS Next 2Y31.09%
EPS Next 3Y20.41%
EPS Next 5Y10.05%
Revenue 1Y (TTM)-63.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-90.17%
Revenue Next Year-31.51%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-42.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-73.49%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.68%
OCF growth 3YN/A
OCF growth 5YN/A

SURROZEN INC / SRZN FAQ

What is the ChartMill fundamental rating of SURROZEN INC (SRZN) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SRZN.


What is the valuation status of SURROZEN INC (SRZN) stock?

ChartMill assigns a valuation rating of 1 / 10 to SURROZEN INC (SRZN). This can be considered as Overvalued.


Can you provide the profitability details for SURROZEN INC?

SURROZEN INC (SRZN) has a profitability rating of 0 / 10.


Can you provide the financial health for SRZN stock?

The financial health rating of SURROZEN INC (SRZN) is 4 / 10.